Sign In
Buy STVN
$18.53
-0.260 (-1.38%)
At Close: Jun 03, 2026
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
05:45pm, Wednesday, 03'rd Jun 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceuti
Implied Volatility Surging for Stevanato Stock Options
12:51pm, Wednesday, 03'rd Jun 2026
Investors need to pay close attention to STVN stock based on the movements in the options market lately.
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
02:00pm, Tuesday, 12'th May 2026
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
05:31pm, Thursday, 07'th May 2026
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates
08:46am, Thursday, 07'th May 2026
Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.11 per share a year ago.
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
06:30am, Thursday, 07'th May 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Stevanato Group to Participate in Three Upcoming Investor Conferences
05:45pm, Monday, 04'th May 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Thursday, 30'th Apr 2026
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conestoga Capital SMid Cap Composite Q1 2026 Portfolio Holdings
03:29pm, Monday, 27'th Apr 2026
The Conestoga SMid Cap Composite returned -10.24% net-of-fees in the first quarter, lagging the Russell 2500 Growth Index's return of -3.52%. RBC's performance was driven by continued strength in aero
Reviewing Stevanato Group (NYSE:STVN) and Heatwurx (NASDAQ:PCSA)
01:28am, Monday, 27'th Apr 2026
Heatwurx (NASDAQ: PCSA - Get Free Report) and Stevanato Group (NYSE: STVN - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
04:05pm, Thursday, 23'rd Apr 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
ArrowMark Colorado Holdings LLC Grows Position in Stevanato Group S.p.A. $STVN
04:26am, Sunday, 15'th Mar 2026
ArrowMark Colorado Holdings LLC increased its holdings in Stevanato Group S.p.A. (NYSE: STVN) by 6.7% in the undefined quarter, according to its most recent filing with the SEC. The institutional inve
Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Recommendation of “Moderate Buy” by Analysts
03:25am, Sunday, 15'th Mar 2026
Shares of Stevanato Group S.p.A. (NYSE: STVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
04:45pm, Thursday, 12'th Mar 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Stevanato: Strong Q4 Results Reinforce Long-Term Growth Story
04:28am, Friday, 06'th Mar 2026
Stevanato Group is reiterated as a Buy, supported by strong Q4/FY25 results and robust long-term demand drivers. While the Engineering division continues to weigh on margins and reported less than €
